ArticleFrontiers in oncology2023

Salvage lenvatinib/everolimus combination therapy after immune checkpoint inhibitor and VEGFR tyrosine kinase inhibitor for metastatic renal cell carcinoma.

Christopher Kwok et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.